1. 90Y-DOTA-Nimotuzumab: Synthesis of a Promising β− Radiopharmaceutical
- Author
-
Silvio Morganti, Riccardo Faccini, Ilaria Fratoddi, Iole Venditti, Marco Chinol, Massimo Castagnola, Federica Marini, Francesco Collamati, Dante Rotili, Isabella Bruno, Carlo Mancini-Terraciano, V. Bocci, Antonella Cartoni, Elena Solfaroli Camillocci, Daria Maccora, Alessandro Giordano, Teresa Scotognella, Scotognella, T., Maccora, D., Bruno, I., Chinol, M., Castagnola, M., Collamati, F., Mancini-Terraciano, C., Morganti, S., Bocci, V., Solfaroli Camillocci, E., Rotili, D., Cartoni, A., Fratoddi, I., Marini, F., Venditti, I., Faccini, R., and Giordano, A.
- Subjects
Immunoconjugates ,medicine.drug_class ,Radioimmunoconjugate ,Antineoplastic Agents ,Antibodies, Monoclonal, Humanized ,radiopharmaceutical ,Monoclonal antibody ,Antibodies ,Antineoplastic Agent ,90Y-DOTA-nimotuzumab ,molecular probe technique ,monoclonalantibody ,radio-guided surgery ,chemistry.chemical_compound ,Heterocyclic Compounds ,Yttrium Radioisotope ,Monoclonal ,Organometallic Compounds ,medicine ,Humans ,Nimotuzumab ,DOTA ,Yttrium Radioisotopes ,Radiology, Nuclear Medicine and imaging ,Humanized ,neoplasms ,Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA ,Organometallic Compound ,Pharmacology ,Chemistry ,Radiochemistry ,Heterocyclic Compound ,Antibodies, Monoclonal ,immunochemotherapy ,monoclonal antibody ,Human plasma ,Radiopharmaceuticals ,Human ,medicine.drug ,Conjugate - Abstract
Background:: Nimotuzumab is a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, nowadays used for tumour immunochemotherapy. This study aimed to label the conjugate DOTA-nimotuzumab with yttrium-90, in order to provide a β- emitting radioimmunoconjugate (90Y-DOTA-nimotuzumab) potentially useful to assess the feasibility of a new radio-guided surgery approach. Methods:: The synthesis of 90Y-DOTA-nimotuzumab was performed in two days. Nimotuzumab was conjugated with a 50 fold excess of DOTA and then labelled with 90Y3+. The 90Y-DOTA-nimotuzumab preparation was optimized considering several parameters such as pH, temperature and reaction volume. Moreover, the 90Y-DOTA-nimotuzumab stability was evaluated in human plasma. Results:: The radioimmunoconjugate 90Y-DOTA-nimotuzumab was obtained with a radiochemical purity greater than 96%, and showed a good stability at 20°C as well as at 37°C in human plasma. Conclusions:: The optimized conditions for a mild and easy preparation of 90Y-DOTA-nimotuzumab joined to a promising stability under physiological conditions suggest to propose this radioimmunoconjugate as a potential diagnostic radiopharmaceutical for β- radio-guided surgery.
- Published
- 2022
- Full Text
- View/download PDF